Bronchodilators for hyperinflation in COPD associated with biomass smoke: clinical trial
Received 12 January 2019
Accepted for publication 12 April 2019
Published 6 August 2019 Volume 2019:14 Pages 1753—1762
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Ms Justinn Cochran
Peer reviewer comments 2
Editor who approved publication: Dr Richard Russell
Alejandra Ramírez-Venegas,1 Mónica Velázquez-Uncal,1 Adrián Aranda-Chávez,1 Nicolás Eduardo Guzmán-Bouilloud,1 María Eugenia Mayar-Maya,2 José Luis Pérez Lara-Albisua,1 Rafael de Jesus Hernández-Zenteno,3 Fernando Flores-Trujillo,3 Raúl H Sansores4
1Department of Tobacco Smoking and COPD Research, Instituto Nacional de Enfermedades Respiratorias “Ismael Cosió Villegas”, Mexico City, Mexico; 2Department of Medical Attention, Instituto Nacional de Enfermedades Respiratorias “Ismael Cosió Villegas”, Mexico City, Mexico; 3Obstructive Disease Ward, Pulmonary Obstructive Diseases Clinical Service, Instituto Nacional de Enfermedades Respiratorias “Ismael Cosío Villegas”, Mexico City, Mexico; 4Department of Respiratory Medicine, Medica Sur Clinic & Foundation, Mexico City, Mexico
Introduction: The efficacy of long-acting bronchodilators for COPD associated with biomass (BE-COPD) has not been properly evaluated.
Objective: To determine the acute effect of indacaterol (IND) 150 μg q.d and tiotropium (TIO) 18 μg q.d. on lung hyperinflation, walking distance (WD) and dyspnea during the six-minute walking test (6MWT) in moderate BE-COPD at 30, 60 and 240 mins post-drug administration.
Design: Randomized, controlled, open-level, crossover noninferiority clinical trial. Forty-two women with BE-COPD were randomly assigned to a bronchodilator sequence: IND–TIO or vice versa.
Results: There were statistically significant changes over time in inspiratory capacity (IC) (p<0.0001), FEV1 (p<0.0001) and FVC (p<0.0001) when IND was used. When TIO was administered, an increase over all time periods was observed only for FEV1 (p<0.0001) and FVC (p<0.0001), whereas for IC an increase was observed only at 30 mins and 24 hrs after TIO administration. We did not find clinically significant increases in WD and dyspnea after the administration of both bronchodilators.
Conclusion: Both IND and TIO showed significant and fast onset improvement in hyperinflation. Therefore, either of them may be recommended as a first line of treatment for COPD associated with BE-COPD.
Keywords: indacaterol, tiotropium, biomass exposure, inspiratory capacity, spirometry, six-minute walking test
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]